- Conditions
- Prostate Cancer
- Interventions
- enzastaurin, placebo, docetaxel, prednisone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 22
- States / cities
- Fullerton, California • Los Angeles, California • Northridge, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms, Breast
- Interventions
- lapatinib, docetaxel, trastuzumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Prostate Cancer, Pain
- Interventions
- Azacitidine, Docetaxel, Prednisone, GADD45α methylation and expression analysis, Pegfilgrastim, Filgrastim
- Drug · Genetic
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Cancer
- Interventions
- calcitriol, docetaxel
- Drug
- Lead sponsor
- Novacea
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 159
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Anchorage, Alaska + 132 more
- Conditions
- Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
- Interventions
- Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars), Birinapant, Venetoclax, Gemcitabine, Docetaxel, Azacitidine
- Drug
- Lead sponsor
- IGM Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more
- Conditions
- Breast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast Cancer, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, Stage II Breast Cancer, Stage III Breast Cancer
- Interventions
- Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery
- Biological · Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
- Interventions
- lorigerlimab, docetaxel, Prednisone
- Biological · Drug
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 10
- States / cities
- Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2)
- Drug
- Lead sponsor
- Jina Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Columbus, Georgia • Springfield, Missouri • Canton, Ohio
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Eribulin, TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Pleasant Hill, California • San Diego, California + 10 more
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- Crizotinib, Enzalutamide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- docetaxel, paclitaxel poliglumex
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 35
- States / cities
- Hoover, Alabama • Tucson, Arizona • Springdale, Arkansas + 32 more
- Conditions
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Interventions
- Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Nab-paclitaxel, Cisplatin, 5Fluorouracil, Cyclophosphamide, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6301, Aldoxorubicin, Avelumab, ALT-803, haNK, Docetaxel, carboplatin
- Drug · Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- NSCLC Stage IV, NSCLC Stage IIIB
- Interventions
- Ipatasertib
- Drug
- Lead sponsor
- Jun Zhang, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 2 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Magrolimab, Pembrolizumab, Docetaxel, 5-FU, Cisplatin, Carboplatin, Zimberelimab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Chandler, Arizona • Duarte, California • Los Angeles, California + 19 more
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
- Interventions
- Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 17
- States / cities
- Cerritos, California • Encino, California • Orange, California + 14 more
- Conditions
- Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma, Refractory Cancer, Coldrhood Cancer
- Interventions
- Tariquidar
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- ADT+Docetaxel+Enzalutamide
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Metastatic Soft Tissue Sarcoma
- Interventions
- MORAb-004, Gemcitabine, Docetaxel, Placebo
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 19
- States / cities
- Santa Monica, California • Jacksonville, Florida • Miami, Florida + 15 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Androgen Hormonal Suppression and Radiation, Androgen Suppression Therapy and Radiation Therapy
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 30 Years and older · Male only
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
- Interventions
- Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- docetaxel
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Trastuzumab emtansine
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Advanced Unresectable or Metastatic Solid Malignancy
- Interventions
- Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 38
- States / cities
- Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more